scientific programme
30
Monday, 23 June 2014
S-09
SYMPOSIUM
15:00–17:00
Room 11
Track: Translational
Topic: Neuroimaging (B)
Neuroimaging vulnerability to neuropsy-
chiatric disorders
Chair:
Marco Leyton, Canada
Co-Chair: Oliver D. Howes, United Kingdom
S-09-001
Using neuroimaging to identify neural mark-
ers of familial vulnerability to depression
Beata Godlewska, United Kingdom
S-09-002
Neuroimaging the vulnerability to depres-
sion: The glutamate system
Gregor Hasler, Switzerland
S-09-003
What underlies the onset of psychosis?
Multi-modal and longitudinal imaging data
from people at risk of psychosis
Oliver D. Howes, United Kingdom
S-09-004
PET studies of dopamine responses in sub-
jects at risk for substance use disorders
Marco Leyton, Canada
Learning Objectives:
This symposium pres-
ents neuroimaging findings that are seeking
to determine what causes vulnerability to neu-
ropsychiatric disorders.
S-10
SYMPOSIUM
15:00–17:00
Room 10
Track: Translational
Topic: Neurodegenerative disorders, incl.
Parkinson‘s Disease; Alzheimer‘s Disease;
Huntington‘s Disease; Fronto-Temporal De-
mentia; Vascular Dementia (A)
Coming of age for phosphodiesterase in-
hibitors as central nervous system thera-
peutics
Chair:
Jos Prickaerts, The Netherlands
Co-Chair: Lawrence Wennogle, USA
S-10-001
Role of PDE-mediated signaling and its
crosstalk in brain function
Akinori Nishi, Japan
M. Kuroiwa, T. Shuto, G. Snyder
S-10-002
Role of cyclic nucleotides in cognitive func-
tion in the brain
Lawrence Wennogle, USA
S-10-003
PDE4 and PDE5 inhibitors in cognition en-
hancement: From animals to humans and
back again
Jos Prickaerts, The Netherlands
S-10-004
Differential effects of PDE2, 4, 9 and 10 inhi-
bition on biochemical and behavioral mark-
ers of striatal function
Christopher Schmidt, USA
Learning Objectives:
This symposium will
give an overview of how phosphodiesterase
inhibitors can be targeted by central nervous
system drugs to give therapeutic benefits.
